Join to View Full Profile
DUMC 3198, 25178 Morris BuildingDurham, NC 27710
Phone+1 919-681-9509
Dr. Stinchcombe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Thomas Stinchcombe, MD, is an oncology specialist based in Durham, NC, with a subspecialty in thoracic cancer. He completed his residency in Internal Medicine at the University of Michigan (1995-1998) and his fellowship in Hematology and Medical Oncology at the University of North Carolina Hospitals (1998-2001). His research focuses on thoracic oncology, which is reflected in his publications in prominent journals such as the Journal of Clinical Oncology and Lung Cancer. Dr. Stinchcombe is actively involved in clinical trials addressing advanced and metastatic non-small cell lung cancer and holds multiple CMS Meaningful Use Certifications from Epic Systems Corporation.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1998 - 2001
University of MichiganResidency, Internal Medicine, 1995 - 1998
University of Virginia School of MedicineClass of 1995
Certifications & Licensure
NC State Medical License 1998 - 2026
MI State Medical License 1995 - 1998
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2006 Jan 01
- Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01
- Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC Start of enrollment: 2006 Mar 01
Publications & Presentations
PubMed
- Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.Eziafa I Oduah, Tian Zhang, Sin-Ho Jung, Thomas E Stinchcombe, Neal Ready
Future Oncology. 2026-04-01 - 3 citationsChemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.Kristin A Higgins, Chen Hu, Helen J Ross, Salma K Jabbour, David E Kozono
Journal of Clinical Oncology. 2026-03-10 - PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.Allison Booth, Shauna Hillman, Kristina Laumann, Ying-Qi Zhao, Michael LeBlanc
Journal of Thoracic Oncology. 2026-02-24
Press Mentions
Empowering Patients with ALK+ NSCLC: The Value of a Shared Decision Aid for First-Line TherapySeptember 8th, 2025- Role of Neoadjuvant Targeted Therapies Remains Unclear in NSCLCAugust 1st, 2025
- Taletrectinib Approved for NSCLCJune 11th, 2025
Grant Support
- Clinical Trial: Phase I Trial Of Abraxane In Combination With Gemcitabine In SolNational Center For Research Resources2008
- Clinical Trial: Cisplatin/Etoposide Or Carboplatin/Pemetrexed In Patients With SNational Center For Research Resources2008
- Phase I Trial Of Abraxane In Combination With Gemcitabine In Solid TumorsNational Center For Research Resources2007
- Lccc 0412: Phase I Carboplatin And Abraxane In Patients With Solid TumorsNational Center For Research Resources2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
